The SU2C-Farrah Fawcett Foundation Human Papillomavirus (HPV) Translational Research Team Grant will commit one million dollars over a three-year period to fund a research project that addresses critical problems in HPV-related cancers and can deliver near-term patient benefit via a multidisciplinary research Team.
The mission of the Farrah Fawcett Foundation is to provide funding for cutting edge cancer research, to support prevention and awareness, and to help those struggling with cancer today. Farrah Fawcett was diagnosed with anal cancer in 2006. She established the Foundation before her death in 2009.
“We’re so pleased to partner with SU2C in this exciting research project. Farrah wanted to ‘make a difference’ in the fight against cancer and I believe that this collaboration of leading researchers in the field of HPV-related cancers will do just that,” said Alana Stewart, president of the Farrah Fawcett Foundation.
HPV is believed to be responsible for virtually all cervical cancers and many anal, vaginal, vulvar, penile cancers, and oropharyngeal cancers.
“We are proud to partner with the Farrah Fawcett Foundation to support urgently needed research on HPV-related cancers,” said Sung Poblete, President and CEO of Stand Up To Cancer. “Through collaboration, we increase our chances for success and accelerate the pace at which developments in the lab can reach patients in the clinic, which is at the very core of the SU2C mission.”
On Stand Up To Cancer’s behalf, the American Association for Cancer Research (AACR), its scientific partner, will issue a call for ideas later this month.
A SU2C-Farrah Fawcett Foundation Joint Scientific Advisory Committee will solicit and review research proposals that focus on achieving near-term clinical benefit to patients with HPV-related cancers and that include two lead researchers and their groups from within one research institution or across two collaborating institutions. Proposed projects should be multidisciplinary and may focus on: new promising treatment modalities; investigation of molecular mechanisms by which HPV causes cancer to develop and metastasize; development of a new generation of targeted treatments; or, improved or novel methods of either diagnosing HPV-related cancers or monitoring the effects of treatment.